Saturday 17 October 2026 Export KYTX’s income statement to Excel — free account

Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $7.0 million. In the quarter to June 2026, EPS grew 35.1%, free cash flow fell 27.1% and total debt rose 95,603.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

5.67 0.30 −5.03%

Follow KYTX

Alert me

Market cap: $369.2M
P/E: 0.0×
Fwd P/E: −1.2×
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 2.00

Total sells 0.29

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	2	—	—	—	—	—	—	—	—	—	—
Sell	—	1	—	—	—	—	—	—	—	—	—	—

Insider Ownership 36.04%

Capital & Financial Ratios $m

Market Cap 369.21

Revenue —

Net Income (152.64)

Free Cash Flow (158.98)

Net Debt (174.54)

Current Ratio 9.06

Debt/Equity 0.15

P/E ratio 0.00

Fwd P/E (1.16)

P/S ratio 0.00

P/B ratio 2.09

Past 5Y EPS Growth —

This Y EPS Growth 24.15%

Next Y EPS Growth (12.84%)

Next Y revenue growth (46.62%)

Next 5Y EPS Growth 10.13%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	58	286	279	199
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	61	291	283	207

	2023	2024	2025	Q'26
Payables	4	5	5	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	20	34	36	23

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	—	0.00%
Earnings	—	—	0.00%
Book Value	—	—	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(42)	(40)	—	—	—
’25	(45)	(32)	(43)	(34)	(154)
’24	(26)	(24)	(27)	(37)	(114)
’23	(11)	(11)	(11)	(19)	(52)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(42)	(41)	—	—	—
’25	(45)	(32)	(43)	(34)	(154)
’24	(26)	(25)	(28)	(38)	(116)
’23	(11)	(11)	(11)	(19)	(53)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.66)	(0.63)	—	—	—
’25	(1.03)	(0.97)	(0.85)	(0.80)	(3.64)
’24	(1.12)	(0.67)	(0.80)	(0.88)	(3.33)
’23	(12.10)	(20.85)	(23.26)	(33.36)	(89.61)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	—	—	3.54	1.78	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	—	—	35.06	13.67
People
People	Employees	—	—	—	—	—	—	84	96	112	130
	Revenue/emp, $m	—	—	—	—	—	—	0.08	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	7	—	—	—
	Gross margin, %	—	—	—	—	—	—	100.00	—	—	—
	EBT	—	—	—	—	—	—	(29)	(60)	(127)	(161)
	EBT margin, %	—	—	—	—	—	—	(411.29)	0.00	0.00	0.00
	Net income	—	—	—	—	—	—	(29)	(60)	(127)	(161)
	Depreciation	—	—	—	—	—	—	1	2	2	2
Per share, $
Per share, $	Revenue	—	—	—	—	—	—	15.42	0.00	0.00	0.00
	Earnings	—	—	—	—	—	—	(63.43)	(89.61)	(3.33)	(3.64)
	Cash flow	—	—	—	—	—	—	(79.28)	(77.76)	(2.98)	(3.47)
	Capex	—	—	—	—	—	—	(1.69)	(0.92)	(0.06)	0.00
	Free cash flow	—	—	—	—	—	—	(80.97)	(78.68)	(3.04)	(3.47)
	Book value	—	—	—	—	—	—	(162.45)	(194.95)	6.95	5.25
	Shares, m	—	—	—	—	—	—	0	1	38	44
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	0.00	—	—	—
	P/S	—	—	—	—	—	—	0.00	—	—	—
	P/B	—	—	—	—	—	—	0.00	—	—	—
	EV/Sales	—	—	—	—	—	—	0.00	—	—	—
	EV/FCF	—	—	—	—	—	—	0.69	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	—	(36)	(52)	(114)	(154)
	Capex	—	—	—	—	—	—	(1)	(1)	(2)	0
	Free cash flow	—	—	—	—	—	—	(37)	(53)	(116)	(154)
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	—	41	41	257	246
	Total debt	—	—	—	—	—	—	1	1	0	25
	Net debt	—	—	—	—	—	—	(50)	(57)	(286)	(255)
	Shareholders’ equity	—	—	—	—	—	—	(74)	(131)	267	232
Returns, %
Returns, %	ROA	—	—	—	—	—	—	0.00	(84.95)	(67.12)	(53.91)
	ROIC	—	—	—	—	—	—	0.00	0.00	0.00	0.00
	ROE	—	—	—	—	—	—	0.00	58.78	(188.59)	(64.67)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RZLT Rezolute, Inc.	$377.2M	— (loss-making)	—	—	n/m	+40.23% (above 0%: growing)	0.00%	0.00%	Compare
EDIT Editas Medicine, Inc.	$374.7M	— (loss-making)	— (loss-making)	+232.31% (above 0%: growing)	n/m	+40.72% (above 0%: growing)	100.00%	(156.05%)	Compare
GALT Galectin Therapeutics Inc.	$374.2M	— (loss-making)	—	—	n/m	+63.06% (above 0%: growing)	0.00%	0.00%	Compare
KYTX Kyverna Therapeutics, Inc.	$369.2M	— (loss-making)	— (loss-making)	—	n/m	−27.06% (below 0%: shrinking)	—	0.00%
AVIR Atea Pharmaceuticals, Inc.	$363.3M	— (loss-making)	— (loss-making)	+295.16% (above 0%: growing)	n/m	+85.53% (above 0%: growing)	0.00%	0.00%	Compare
FENC Adherex Technologies Inc.	$362.9M	— (loss-making)	31.4×	+85.18% (above 0%: growing)	n/m	+101.36% (above 0%: growing)	95.97%	9.72%	Compare
TTRX Turn Therapeutics Inc.	$345.3M	— (loss-making)	—	—	n/m	−74.76% (below 0%: shrinking)	—	0.00%	Compare
OBIO Orchestra BioMed Holdings, Inc.	$345.0M	— (loss-making)	— (loss-making)	−89.47% (below 0%: shrinking)	n/m	−25.87% (below 0%: shrinking)	71.59%	(25,404.55%)	Compare
CCCC C4 Therapeutics, Inc.	$342.0M	— (loss-making)	— (loss-making)	+2.75% (above 0%: growing)	n/m	+86.84% (above 0%: growing)	100.00%	(397.88%)	Compare
Median of peers	$363.1M	—	—	+85.18%	—	+51.89%	71.59%	0.00%

All 614 Biotechnology stocks →

Kyverna Therapeutics, Inc. (KYTX) key facts

Kyverna Therapeutics, Inc. (KYTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Kyverna Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $7.0 million.
As of October 16, 2026, KYTX traded at $5.67, a market capitalization of $369.2 million.
Return on equity was −64.7% and debt-to-equity 0.15.

Source: company filings (standardised) and stockrow calculations.